Hamilton B A, Jones P G, Hoda A N, Keane P M, Majid I, Zaidi S I
Pharmatherapeutica. 1989;5(5):292-7.
Seventy-two depressed patients attending general practices were randomly allocated to treatment with either flupenthixol dihydrochloride (1 to 2 mg/day) or fluvoxamine maleate (100 to 200 mg/day) to assess efficacy and side-effects over a 4-week period. Clinical assessments were carried out before medication (Day 1) and on Days 8, 15 and 29 of treatment using the Hamilton Rating Scale for Depression, Clinical Global Impressions (CGI) and a patient self-assessment visual analogue scale for depression. Unwanted symptoms were also recorded. Reduction in mean total scores on the Hamilton scale at each assessment and therapeutic effect improvement on the CGI were greater for patients treated with flupenthixol (p less than 0.05). Reduction in unwanted symptoms was progressive in both groups, but more pronounced in patients receiving flupenthixol. Twice as many new symptoms arose in the fluvoxamine group compared to the flupenthixol group. Four patients were withdrawn in the fluvoxamine group due to untoward drug effects compared with none in the flupenthixol group.
72名在普通诊所就诊的抑郁症患者被随机分配接受二盐酸氟哌噻吨(1至2毫克/天)或马来酸氟伏沙明(100至200毫克/天)治疗,以评估4周内的疗效和副作用。在用药前(第1天)以及治疗的第8、15和29天,使用汉密尔顿抑郁评定量表、临床总体印象量表(CGI)和患者自我评估的抑郁视觉模拟量表进行临床评估。还记录了不良症状。接受氟哌噻吨治疗的患者在每次评估时汉密尔顿量表平均总分的降低以及CGI上治疗效果的改善更大(p小于0.05)。两组中不良症状的减少都是渐进的,但在接受氟哌噻吨治疗的患者中更为明显。与氟哌噻吨组相比,氟伏沙明组出现的新症状数量是其两倍。氟伏沙明组有4名患者因药物不良反应而退出,而氟哌噻吨组无一人退出。